{"id":"https://openalex.org/W2116368558","doi":"https://doi.org/10.1158/1535-7163.mct-14-0248","title":"The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor","display_name":"The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor","publication_year":2014,"publication_date":"2014-08-29","ids":{"openalex":"https://openalex.org/W2116368558","doi":"https://doi.org/10.1158/1535-7163.mct-14-0248","mag":"2116368558","pmid":"https://pubmed.ncbi.nlm.nih.gov/25169980"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-14-0248","doi":"https://doi.org/10.1158/1535-7163.mct-14-0248","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0248","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102288131","display_name":"Yoshito Nakanishi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Yoshito Nakanishi","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073494688","display_name":"Nukinori Akiyama","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Nukinori Akiyama","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023691479","display_name":"Toshiyuki Tsukaguchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshiyuki Tsukaguchi","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007750749","display_name":"Toshihiko Fujii","orcid":"https://orcid.org/0009-0006-0866-6458","observed_orcids":["https://orcid.org/0009-0006-0866-6458"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshihiko Fujii","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079364150","display_name":"Kiyoaki Sakata","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kiyoaki Sakata","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073599331","display_name":"Hitoshi Sase","orcid":"https://orcid.org/0009-0000-8305-1732","observed_orcids":["https://orcid.org/0009-0000-8305-1732"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hitoshi Sase","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047187066","display_name":"Takehito Isobe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takehito Isobe","raw_affiliation_strings":["2Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046638760","display_name":"Kenji Morikami","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kenji Morikami","raw_affiliation_strings":["2Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086921634","display_name":"Hidetoshi Shindoh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hidetoshi Shindoh","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051079897","display_name":"Toshiyuki Mio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshiyuki Mio","raw_affiliation_strings":["Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan. Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan. Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063209300","display_name":"Hirosato Ebiike","orcid":"https://orcid.org/0000-0001-9471-8205","observed_orcids":["https://orcid.org/0000-0001-9471-8205"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hirosato Ebiike","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074328938","display_name":"Naoki Taka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Naoki Taka","raw_affiliation_strings":["2Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108748469","display_name":"Yuko Aoki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yuko Aoki","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5037187028","display_name":"Nobuya Ishii","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Nobuya Ishii","raw_affiliation_strings":["1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan","institution_ids":["https://openalex.org/I4405254473"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5102288131"],"corresponding_institution_ids":["https://openalex.org/I4405254473"],"apc_list":null,"apc_paid":null,"fwci":4.2961,"has_fulltext":false,"cited_by_count":121,"citation_normalized_percentile":{"value":0.9601877,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":100},"biblio":{"volume":"13","issue":"11","first_page":"2547","last_page":"2558"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13779","display_name":"Cancer Mechanisms and Therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fgfr-inhibitors","display_name":"FGFR inhibitors","score":0.8259999752044678},{"id":"https://openalex.org/keywords/fibroblast-growth-factor-receptor","display_name":"fibroblast growth factor receptor","score":0.906000018119812},{"id":"https://openalex.org/keywords/fgfr1","display_name":"FGFR1","score":0.7749999761581421},{"id":"https://openalex.org/keywords/fgfr2","display_name":"FGFR2","score":0.9900000095367432},{"id":"https://openalex.org/keywords/fgfr3","display_name":"FGFR3","score":1.0},{"id":"https://openalex.org/keywords/gatekeeper-mutations","display_name":"gatekeeper mutation","score":0.6859999895095825},{"id":"https://openalex.org/keywords/kinase-inhibitor-selectivity","display_name":"kinase selectivity","score":0.5329999923706055},{"id":"https://openalex.org/keywords/atp-binding-site","display_name":"ATP binding site","score":0.7490000128746033},{"id":"https://openalex.org/keywords/cancer-cell-line-panel","display_name":"cancer cell line panel","score":0.6420000195503235},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.9300000071525574},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.6790000200271606},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7319999933242798}],"concepts":[{"id":"https://openalex.org/C82867764","wikidata":"https://www.wikidata.org/wiki/Q24780051","display_name":"Fibroblast growth factor receptor","level":4,"score":0.8694217801094055},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5370333194732666},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.44750508666038513},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4319073259830475},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.42083877325057983},{"id":"https://openalex.org/C74373430","wikidata":"https://www.wikidata.org/wiki/Q24727126","display_name":"Fibroblast growth factor","level":3,"score":0.4094610810279846},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3616306781768799},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3534635305404663},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34000885486602783}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004354","descriptor_name":"Drug Screening Assays, Antitumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007150","descriptor_name":"Immunohistochemistry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011897","descriptor_name":"Random Allocation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014162","descriptor_name":"Transfection","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017208","descriptor_name":"Rats, Wistar","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017468","descriptor_name":"Receptors, Fibroblast Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D017468","descriptor_name":"Receptors, Fibroblast Growth Factor","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.mct-14-0248","doi":"https://doi.org/10.1158/1535-7163.mct-14-0248","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0248","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:25169980","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25169980","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:dora:psi_8445","doi":null,"is_oa":false,"landing_page_url":"https://www.dora.lib4ri.ch/psi/item/psi:8445","pdf_url":null,"source":{"id":"https://openalex.org/S4306402574","display_name":"DORA PSI (Paul Scherrer Institute)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2802229908","host_organization_name":"Paul Scherrer Institute","host_organization_lineage":["https://openalex.org/I2802229908"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320333003","display_name":"Chugai Pharmaceutical","ror":"https://ror.org/01vepzj85"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":48,"referenced_works":["https://openalex.org/W1483620247","https://openalex.org/W1563019250","https://openalex.org/W1566932673","https://openalex.org/W1964306758","https://openalex.org/W1977565331","https://openalex.org/W1979702889","https://openalex.org/W1979906615","https://openalex.org/W1982643760","https://openalex.org/W1988476050","https://openalex.org/W1991166678","https://openalex.org/W1992331688","https://openalex.org/W1997476230","https://openalex.org/W2000292756","https://openalex.org/W2002937040","https://openalex.org/W2003984225","https://openalex.org/W2005036868","https://openalex.org/W2019711215","https://openalex.org/W2026548544","https://openalex.org/W2030500412","https://openalex.org/W2035346960","https://openalex.org/W2043398720","https://openalex.org/W2043789128","https://openalex.org/W2047510068","https://openalex.org/W2066417528","https://openalex.org/W2066523881","https://openalex.org/W2088123597","https://openalex.org/W2093090488","https://openalex.org/W2096950509","https://openalex.org/W2097373408","https://openalex.org/W2098320019","https://openalex.org/W2101844536","https://openalex.org/W2106638424","https://openalex.org/W2107977954","https://openalex.org/W2112463549","https://openalex.org/W2113235293","https://openalex.org/W2118155696","https://openalex.org/W2121637291","https://openalex.org/W2125789330","https://openalex.org/W2129058753","https://openalex.org/W2130440144","https://openalex.org/W2134165163","https://openalex.org/W2136448063","https://openalex.org/W2137758263","https://openalex.org/W2141134269","https://openalex.org/W2161730969","https://openalex.org/W2167188058","https://openalex.org/W2169816570","https://openalex.org/W2275877493"],"related_works":["https://openalex.org/W1548773947","https://openalex.org/W1510758377","https://openalex.org/W2549346602","https://openalex.org/W2740752959","https://openalex.org/W2496478693","https://openalex.org/W1969012061","https://openalex.org/W2138272238","https://openalex.org/W1446747868","https://openalex.org/W4282927683","https://openalex.org/W3111143707"],"abstract_inverted_index":{"The":[0],"FGF":[1],"receptors":[2],"(FGFR)":[3],"are":[4,8],"tyrosine":[5],"kinases":[6],"that":[7,31,98,190],"constitutively":[9],"activated":[10],"in":[11,54,70,109,160,169],"a":[12,73,88,100,161],"subset":[13],"of":[14,56,85,113,163,173,186,212],"tumors":[15],"by":[16],"genetic":[17,60,158,216],"alterations":[18,159],"such":[19,71],"as":[20,37,39],"gene":[21],"amplifications,":[22],"point":[23],"mutations,":[24],"or":[25,44,116,135],"chromosomal":[26],"translocations/rearrangements.":[27],"Recently,":[28],"small-molecule":[29],"inhibitors":[30,196],"can":[32,180],"inhibit":[33,129,181],"the":[34,40,83,110,187,210],"FGFR":[35,59,75,144,157,195,215],"family":[36,50],"well":[38],"VEGF":[41],"receptor":[42,48,133],"(VEGFR)":[43],"platelet-derived":[45],"growth":[46],"factor":[47],"(PDGFR)":[49],"displayed":[51,148],"clinical":[52,207],"benefits":[53],"cohorts":[55],"patients":[57,213],"with":[58,106,139,155],"alterations.":[61,217],"However,":[62],"to":[63,193],"achieve":[64],"more":[65],"potent":[66],"and":[67,90,95,124,168,197],"prolonged":[68],"activity":[69,151],"populations,":[72],"selective":[74,89],"inhibitor":[76,97],"is":[77,205],"still":[78],"needed.":[79],"Here,":[80],"we":[81],"report":[82],"identification":[84],"CH5183284/Debio":[86,118,146,178,203],"1347,":[87],"orally":[91],"available":[92],"FGFR1,":[93,114,122],"FGFR2,":[94,115,123],"FGFR3":[96,125],"has":[99],"unique":[101,107,175],"chemical":[102],"scaffold.":[103],"By":[104],"interacting":[105],"residues":[108],"ATP-binding":[111],"site":[112],"FGFR3,":[117],"1347":[119,147,179,204],"selectively":[120],"inhibits":[121],"but":[126],"does":[127],"not":[128],"kinase":[130],"insert":[131],"domain":[132],"(KDR)":[134],"other":[136,194],"kinases.":[137],"Consistent":[138],"its":[140,174],"high":[141],"selectivity":[142],"for":[143,209],"enzymes,":[145],"preferential":[149],"antitumor":[150],"against":[152],"cancer":[153,165],"cells":[154],"various":[156],"panel":[162],"327":[164],"cell":[166],"lines":[167],"xenograft":[170],"models.":[171],"Because":[172],"binding":[176],"mode,":[177],"FGFR2":[182,199],"harboring":[183,214],"one":[184],"type":[185],"gatekeeper":[188],"mutation":[189],"causes":[191],"resistance":[192],"block":[198],"V564F-driven":[200],"tumor":[201],"growth.":[202],"under":[206],"investigation":[208],"treatment":[211]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":17},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":14},{"year":2016,"cited_by_count":18},{"year":2015,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}